Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
2007 1
2019 1
2023 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real-world setting.
Alegre A, Gironella M, Escalante F, Bergua JM, Martínez-Chamorro C, López A, González E, Bárez A, Somolinos N, Persona EP, Cabrera AS, Soler A, Rodríguez BI, López JM, González Y, Giménez VC, Sampol A, Muñoz C, Vilanova D, Durán M, Fernández de Larrea C; Spanish Myeloma Group (GEM_PETHEMA). Alegre A, et al. Among authors: cabrera as. Hemasphere. 2024 Jul 4;8(7):e81. doi: 10.1002/hem3.81. eCollection 2024 Jul. Hemasphere. 2024. PMID: 38974896 Free PMC article.
Evaluation of the synergistic effects of antioxidant activity on mixtures of the essential oil from Apium graveolens L., Thymus vulgaris L. and Coriandrum sativum L. using simplex-lattice design.
Crespo YA, Bravo Sánchez LR, Quintana YG, Cabrera AST, Bermúdez Del Sol A, Mayancha DMG. Crespo YA, et al. Among authors: cabrera ast. Heliyon. 2019 Jun 15;5(6):e01942. doi: 10.1016/j.heliyon.2019.e01942. eCollection 2019 Jun. Heliyon. 2019. PMID: 31245650 Free PMC article.
Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study.
Bravo J, Baltasar Tello P, González Garcia E, Ríos Herranz E, Páyer AR, Terol Castera MJ, Champ D, Medina Perez A, Gironella M, Fernández Zarzoso M, Forés R, Delgado J, Garcia-Marco JA; GABRIELL Study Group/Investigators. Bravo J, et al. Leuk Lymphoma. 2023 May;64(5):913-926. doi: 10.1080/10428194.2023.2216327. Epub 2023 May 31. Leuk Lymphoma. 2023. PMID: 37255002 Clinical Trial.